BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALX-0141: Additional Phase I data

Additional data from a double-blind, placebo-controlled Phase I trial in 42 healthy postmenopausal women showed that 4 of 6 subjects receiving a single subcutaneous injection of 1 mg/kg ALX-0141 had significant...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >